New hope for tough blood cancers? donor immune cells enter early trial
NCT ID NCT07316907
First seen Jan 11, 2026 · Last updated May 06, 2026 · Updated 17 times
Summary
This early study tests whether specially engineered immune cells from a donor (called CAR-T cells) are safe for people with B-cell blood cancers that have not responded to standard treatment or have returned. The trial will enroll 12 adults and aims to find the right dose while watching for side effects. It is a first step to see if this approach can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.